Specify a stock or a cryptocurrency in the search bar to get a summary
Revenio Group Corporation
REG1VRevenio Group Oyj, provides ophthalmological devices and software solutions for the diagnosis of glaucoma, macular degeneration, and diabetic retinopathy in Finland, rest of Europe, North America, and internationally. The company offers iCare IC100 and IC200 tonometers; iCare HOME, a device for self-measurement of eye pressure; and iCare TONOVET an IOP measuring on animal patients by general veterinary practitioners, veterinary ophthalmologists, and other veterinary medical personnel. It also provides imaging devices comprising iCare EIDON AF, a device with confocal retinal imaging; and DRSplus, a device for pupil imaging; and iCare COMPASS, which provides fundus perimetry with true-color confocal retinal images. In addition, the company offers Oculo, an eye care software platform, which combines clinical communication, telehealth, remote patient monitoring and data analytics capabilities. Revenio Group Oyj was incorporated in 2001 and is based in Vantaa, Finland. Address: Aeyritie 22, Vantaa, Finland, 01510
Analytics
WallStreet Target Price
30.06 EURP/E ratio
39.4722Dividend Yield
1.32 %Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures REG1V
Dividend Analytics REG1V
Dividend growth over 5 years
-54 %Continuous growth
2 yearsPayout Ratio 5 years average
68 %Dividend History REG1V
Stock Valuation REG1V
Financials REG1V
Results | 2019 | Dynamics |